Skip to main content

Advertisement

SpringerLink
Log in

An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors

  • Review
  • Published:
Bone Marrow Transplantation Submit manuscript

Abstract

Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML, whereas transplantation remains a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia. Reduced-intensity conditioning has decreased the treatment-related mortality, and advances in the use of alternative donors for transplantation could extend the use of this procedure to an increasing number of patients with improved safety and efficacy. Here we review the current knowledge about allogeneic transplantation for myeloproliferative neoplasms and discuss the most important aspects to be considered when contemplating transplantation for patients with these diseases. Janus kinase 2 inhibitors offer the promise to improve spleen size and performance of patients with myelofibrosis and extend transplantation for patients with more advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vardiman J, Hyjek E . World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants [review]. Hematology/Education Program of the American Society of Hematology American Society of Hematology Education Program 2011; 2011: 250–256.

    Article  Google Scholar 

  2. Tefferi A, Thiele J, Vardiman JW . The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842–3847.

    Article  CAS  PubMed  Google Scholar 

  3. Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.

    Article  CAS  PubMed  Google Scholar 

  4. Radich J . Stem cell transplant for chronic myeloid leukemia in the imatinib era [review]. Semin Hematol 2010; 47: 354–361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    Article  CAS  PubMed  Google Scholar 

  6. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annu Meet Abstr 2009; 114: 1126.

    Google Scholar 

  7. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  8. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  9. Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009; 88: 1237–1247.

    Article  PubMed  Google Scholar 

  10. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.

    Article  CAS  PubMed  Google Scholar 

  11. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112: 3500–3507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.

    Article  CAS  PubMed  Google Scholar 

  13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  PubMed  Google Scholar 

  14. Jabbour E, Cortes J, Santos FPS, Jones D, O'Brien S, Rondon G et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011; 117: 3641–3647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre PD, Chuah C, Nicolini FE et al. Initial findings from the PACE Trial: a pivotal phase 2 study of Ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annu Meet Abstr 2011; 118: 109.

    Google Scholar 

  16. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011; 118: 5697–5700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421–1423.

    Article  CAS  PubMed  Google Scholar 

  18. Jiang Q, Xu L-P, Liu D-H, Liu K, Chen S-S, Jiang B et al. Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia in accelerated phase: a single center experience in China after a 9-year follow-up. ASH Annu Meet Abstr 2010; 116: 2347.

    Google Scholar 

  19. Ahmed S, Chiattone A, Jones R, Sphall EJ, Farhan S, Rondon G et al. Allogeneic stem cell transplantation for CML in second chronic phase after blast crisis in the tyrosine kinase inhibitor era. ASH Annu Meet Abstr 2011; 118: 2039-.

    Google Scholar 

  20. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40: 444–455.

    Article  PubMed  Google Scholar 

  21. Adekola K, di Stasi A, Ferro R, Ahmed S, de Lima MJG, Oran B et al. Safety and efficacy of haploidentical stem cell transplantation for advanced chronic myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: S213–S214.

    Article  Google Scholar 

  22. Tefferi A . Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 141–150.

    Article  CAS  PubMed  Google Scholar 

  23. Gupta V, Hari P, Hoffman R . Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120: 1367–1379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D . Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 2007; 13 ( (Suppl 1) 64–72.

    Article  CAS  PubMed  Google Scholar 

  25. Verstovsek S . Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med 2013; 125: 128–135.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657–2664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.

    Article  PubMed  Google Scholar 

  28. Tefferi A . How I treat myelofibrosis. Blood 2011; 117: 3494–3504.

    Article  CAS  PubMed  Google Scholar 

  29. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458–463.

    Article  CAS  PubMed  Google Scholar 

  30. Vannucchi AM . Management of myelofibrosis. Hematology 2011; 2011: 222–230.

    Article  PubMed  Google Scholar 

  31. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010; 45: 1587–1593.

    Article  CAS  PubMed  Google Scholar 

  32. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358–367.

    Article  PubMed  Google Scholar 

  33. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264–5270.

    Article  PubMed  Google Scholar 

  34. Rondelli D, Goldberg JD, Marchioli R, Isola L, Shore TB, Prchal JT et al. Results of Phase II Clinical Trial MPD-RC 101: allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis. ASH Annu Meet Abstr 2011; 118: 1750.

    Google Scholar 

  35. Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.

    Article  PubMed  Google Scholar 

  36. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572–3581.

    Article  CAS  PubMed  Google Scholar 

  37. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, et al. Allogeneic transplantation for myelofibrosis: b enefit of dose intensity. ASCO Meet Abstr 2013; 31 ( (Suppl) 7011.

    Google Scholar 

  38. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A . Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973–977.

    Article  CAS  PubMed  Google Scholar 

  39. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010; 16: 555–559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121: 2725–2733.

    Article  CAS  PubMed  Google Scholar 

  41. Bacher U, Haferlach T, Schnittger S, Kreipe H, Kroger N . Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153: 149–167.

    Article  PubMed  Google Scholar 

  42. Cheng H, Kirtani VG, Gergis U . Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplant 2012; 47: 535–541.

    Article  CAS  PubMed  Google Scholar 

  43. Onida F, Beran M . Diagnosis and management of chronic myelomonocytic leukemia. Curr Hematol Malign Rep 2008; 3: 31–36.

    Article  Google Scholar 

  44. Parikh SA, Tefferi A . Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 610–619.

    Article  PubMed  Google Scholar 

  45. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375–383.

    Article  PubMed  Google Scholar 

  46. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.

    Article  CAS  PubMed  Google Scholar 

  47. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [Multicenter Study]. Br J Haematol 2002; 118: 67–73.

    Article  PubMed  Google Scholar 

  48. Krishnamurthy P, Lim ZY, Nagi W, Kenyon M, Mijovic A, Ireland R et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 2010; 45: 1502–1507.

    Article  CAS  PubMed  Google Scholar 

  49. Symeonidis A, van Biezen A, Mufti G, Finke J, Beelen D Bornhauser M et al. Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Bone Marrow Transplant 2010; 45 (Suppl 2) S241.

    Google Scholar 

  50. Zang DY, Deeg HJ, Gooley T, Anderson JE, Anasetti C, Sanders J et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110: 217–222.

    Article  CAS  PubMed  Google Scholar 

  51. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011; 17: 908–915.

    Article  PubMed  Google Scholar 

  52. Borthakur G, Beran M, Liu J, Verma D, Dong XQ, Rondon G et al. Outcomes in patients with chronic myelomonocytic leukemia: analysis of 279 patients. ASH Annu Meet Abstr 2008; 112: 3235.

    Google Scholar 

  53. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas M, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [article]. Lancet 2005; 365: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  54. Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 2001; 112: 392–396.

    Article  CAS  PubMed  Google Scholar 

  55. Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 1409–1414.

    Article  PubMed  Google Scholar 

  56. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355–365.

    Article  PubMed  Google Scholar 

  57. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M et al. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant 2012; 18: 1446–1454.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

    K Adekola, U Popat & S O Ciurea

Authors
  1. K Adekola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S O Ciurea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S O Ciurea.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adekola, K., Popat, U. & Ciurea, S. An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Bone Marrow Transplant 49, 1352–1359 (2014). https://doi.org/10.1038/bmt.2014.176

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.176

  • Springer Nature Limited

Search

Navigation